NVO
Price
$45.13
Change
-$2.09 (-4.43%)
Updated
Aug 6, 04:47 PM (EDT)
Capitalization
215.92B
Earnings call today
SLXN
Price
$8.30
Change
-$0.56 (-6.32%)
Updated
Aug 6, 04:51 PM (EDT)
Capitalization
5.13M
Interact to see
Advertisement

NVO vs SLXN

Header iconNVO vs SLXN Comparison
Open Charts NVO vs SLXNBanner chart's image
Novo-Nordisk A/S
Price$45.13
Change-$2.09 (-4.43%)
Volume$93.23K
Capitalization215.92B
Silexion Therapeutics
Price$8.30
Change-$0.56 (-6.32%)
Volume$200
Capitalization5.13M
NVO vs SLXN Comparison Chart in %
Loading...
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NVO vs. SLXN commentary
Aug 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Hold and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 06, 2025
Stock price -- (NVO: $47.22 vs. SLXN: $8.86)
Brand notoriety: NVO and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVO: 151% vs. SLXN: 38%
Market capitalization -- NVO: $215.92B vs. SLXN: $5.13M
NVO [@Biotechnology] is valued at $215.92B. SLXN’s [@Biotechnology] market capitalization is $5.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $215.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVO’s FA Score shows that 2 FA rating(s) are green whileSLXN’s FA Score has 1 green FA rating(s).

  • NVO’s FA Score: 2 green, 3 red.
  • SLXN’s FA Score: 1 green, 4 red.
According to our system of comparison, NVO is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVO’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • NVO’s TA Score: 4 bullish, 6 bearish.
  • SLXN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SLXN is a better buy in the short-term than NVO.

Price Growth

NVO (@Biotechnology) experienced а -12.46% price change this week, while SLXN (@Biotechnology) price change was -28.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.91%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +13.25%.

Reported Earning Dates

NVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (-0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($216B) has a higher market cap than SLXN($5.13M). NVO YTD gains are higher at: -44.221 vs. SLXN (-70.614). NVO has higher annual earnings (EBITDA): 147B vs. SLXN (-16.96M). SLXN has less debt than NVO: SLXN (3.48M) vs NVO (119B). NVO has higher revenues than SLXN: NVO (303B) vs SLXN (0).
NVOSLXNNVO / SLXN
Capitalization216B5.13M4,207,246%
EBITDA147B-16.96M-866,899%
Gain YTD-44.221-70.61463%
P/E Ratio12.95N/A-
Revenue303B0-
Total Cash41.6BN/A-
Total Debt119B3.48M3,417,576%
FUNDAMENTALS RATINGS
NVO: Fundamental Ratings
NVO
OUTLOOK RATING
1..100
55
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
83
SMR RATING
1..100
14
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NVOSLXN
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
8%
Momentum
ODDS (%)
Bearish Trend 2 days ago
58%
Bearish Trend 2 days ago
20%
MACD
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
31%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
42%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
62%
Bearish Trend 2 days ago
51%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 10 days ago
51%
Declines
ODDS (%)
Bearish Trend 7 days ago
58%
Bearish Trend 2 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
44%
Aroon
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
59%
View a ticker or compare two or three
Interact to see
Advertisement
NVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IMCV77.340.11
+0.14%
iShares Morningstar Mid-Cap Value ETF
FCO6.60N/A
N/A
abrdn Global Income Fund
CWS68.59-0.24
-0.35%
AdvisorShares Focused Equity ETF
SDTY44.93-0.19
-0.43%
YieldMax S&P 500 0DTE Cov Cll Stgy ETF
FTEC203.37-1.75
-0.85%
Fidelity MSCI Information Tech ETF

NVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVO
1D Price
Change %
NVO100%
-3.26%
NONOF - NVO
70%
Closely correlated
-3.40%
GMAB - NVO
35%
Loosely correlated
+0.55%
TECH - NVO
35%
Loosely correlated
-0.44%
BCAB - NVO
34%
Loosely correlated
+5.58%
AXON - NVO
29%
Poorly correlated
+16.41%
More

SLXN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLXN has been loosely correlated with IMA. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SLXN jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
-1.99%
IMA - SLXN
59%
Loosely correlated
-0.66%
CELC - SLXN
50%
Loosely correlated
-0.67%
MRSN - SLXN
43%
Loosely correlated
+2.62%
CHRS - SLXN
26%
Poorly correlated
+4.86%
QSI - SLXN
25%
Poorly correlated
N/A
More